Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Abstract

The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

1 - 41 . (canceled)  
   
   
       42 . A method of treating a subject afflicted with dementia which comprises administering to the subject a pharmaceutical composition consisting of an amount of the mesylate salt of R(+)-N-propargyl-1-aminoindan effective to treat the subject and at least one pharmaceutically acceptable carrier.  
   
   
       43 . The method of  claim 42 , wherein the dementia is of the Alzheimer type.  
   
   
       44 . The method of  claim 42 , wherein the subject is human and the effective amount is from about 0.1 mg to about 100 mg per day.  
   
   
       45 . The method of  claim 44 , wherein the effective amount is from about 1 mg to about 10 mg per day.  
   
   
       46 . The method of  claim 45 , wherein the effective amount is 1 mg per day.  
   
   
       47 . The method of  claim 42 , wherein the pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       48 . The method of  claim 47 , wherein the pharmaceutical composition is administered orally.  
   
   
       49 . The method of  claim 46 , wherein pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       50 . The method of  claim 49 , wherein the pharmaceutical composition is administered orally.  
   
   
       51 . A method of treating a subject afflicted with dementia which comprises administering to the subject a pharmaceutical composition consisting essentially of an amount of the mesylate salt of R(+)-N-propargyl-1-aminoindan effective to treat the subject and at least one pharmaceutically acceptable carrier.  
   
   
       52 . The method of claims  51 , wherein the dementia is of the Alzheimer type.  
   
   
       53 . The method of  claim 51 , wherein the subject is human and the effective amount is from about 0.1 mg to about 100 mg per day.  
   
   
       54 . The method of  claim 53 , wherein the effective amount is from about 1 mg to about 10 mg per day.  
   
   
       55 . The method of  claim 54 , wherein the effective amount is 1 mg per day.  
   
   
       56 . The method of  claim 51 , wherein the pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       57 . The method of  claim 56 , wherein the pharmaceutical composition is administered orally.  
   
   
       58 . The method of  claim 55 , wherein the pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       59 . The method of  claim 58 , wherein the pharmaceutical composition is administered orally.  
   
   
       60 . A method of treating a subject afflicted with dementia which comprises administering to the subject a pharmaceutical composition comprising an amount of the mesylate salt of R(+)-N-propargyl-1-aminoindan effective to treat the subject and at least one pharmaceutically acceptable carrier.  
   
   
       61 . The method of claims  60 , wherein the dementia is of the Alzheimer type.  
   
   
       62 . The method of  claim 60 , wherein the subject is human and the effective amount is from about 0.1 mg to about 100 mg per day.  
   
   
       63 . The method of  claim 62 , wherein the effective amount is from about 1 mg to about 10 mg per day.  
   
   
       64 . The method of  claim 63 , wherein the effective amount is 1 mg per day.  
   
   
       65 . The method of  claim 60 , wherein the pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       66 . The method of  claim 65 , wherein the pharmaceutical composition is administered orally.  
   
   
       67 . The method of  claim 64 , wherein the pharmaceutical composition is administered orally, rectally, intravenously, transdermally, or parenterally.  
   
   
       68 . The method of  claim 67 , wherein the pharmaceutical composition is administered orally.